...
首页> 外文期刊>Haemostasis >Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.
【24h】

Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.

机译:rt-PA或链激酶同时加肝素与单独使用肝素相比,在冠状动脉溶栓后凝血酶的产生增加。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This study compares the extent of inhibition of thrombin generation and activity achieved in patients with acute myocardial infarction receiving fibrinolytic treatment (streptokinase SK, or rt-PA) and concomitant intravenous heparin treatment adjusted to the patients' weight with that achieved with the same heparin regimen but without fibrinolytic therapy. The study involved 90 patients, grouped according to their treatment: SK+heparin; rt-PA+heparin, and heparin without thrombolytic agents. Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), fibrinopeptide A (FPA) and activated partial thromboplastin time were measured. Patients treated with SK+heparin or rt-PA+heparin and higher F1+2 plasma levels than the patients treated with heparin alone at 12, 48 and 72 h in the case of SK+heparin, and at 12, 24, 48 and 72 h in that of rt-PA+heparin. Compared to baseline, the plasma levels of FPA were decreased in the three treatment groups at 24-48 h. There were no significant changes in TAT and FPA plasma levels among the three treatment groups at the different times. After thrombolytic therapy with both SK and rt-PA, there was an increase in thrombin generation, although high-dose intravenous heparin inhibited the different increases in thrombin associated with the thrombolytic agents to the same extent.
机译:这项研究比较了接受纤溶治疗(链激酶SK或rt-PA)和根据患者体重调整的静脉肝素治疗(与相同肝素治疗方案相同)对急性心肌梗塞患者凝血酶的抑制程度和活性但没有纤溶疗法。该研究纳入了90名患者,按治疗方案分组:SK +肝素; rt-PA +肝素和无溶栓剂的肝素。测量凝血酶原片段1 + 2(F1 + 2),凝血酶-抗凝血酶复合物(TAT),纤维蛋白肽A(FPA)和活化的部分凝血活酶时间。在SK +肝素的情况下,在12、48和72 h以及在12、24、48和72的情况下,与单独使用肝素的患者相比,接受SK +肝素或rt-PA +肝素治疗的患者的F1 + 2血浆水平更高h在rt-PA +肝素中。与基线相比,三个治疗组在24-48 h时血浆FPA水平降低。三个治疗组在不同时间的TAT和FPA血浆水平无明显变化。尽管大剂量静脉内肝素在相同程度上抑制了与溶栓剂相关的凝血酶的不同增加,但使用SK和rt-PA进行溶栓治疗后,凝血酶的产生有所增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号